HLK Biotech Holding Group Inc (AMHD) fair value: what the stock is really worth
As of Sep 25, 2026: fair value of HLK Biotech Holding Group Inc $0.00, price $0.00, upside +0.0%, quality 31 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch HLK Biotech Holding Group Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
HLK Biotech Holding Group, Inc., through its subsidiaries, produces and sells biodiesel. It also acquires real estate properties. The company was formerly known as Amelot Holdings, Inc. and changed its name to HLK Biotech Holding Group, Inc. in February 2018. HLK Biotech Holding Group, Inc. is headquartered in Norfolk, Virginia.
Stock analysis
HLK Biotech Holding Group Inc (AMHD) currently trades at $0.0002, while our model-based Fair Value estimate is $0.0002, so the stock looks roughly fairly valued today (gap 0.0%).
Show more
Valuation
How firm this estimate is: it rests on 2 models at a data quality of 88/100, which puts the evidence level at low.
Quality & growth
The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
HLK Biotech Holding Group Inc reported revenue of $8.3K in FY2016 versus $0 in FY1997. Reported net income was −$3.8K in FY2016.
Key figures
Market cap $1.3K · Net margin −45.3% · Return on assets (EBIT) −335% · Operating margin −159%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 27 out of 100 (low confidence).
What moves the price
The share trades at its 52-week high and at its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 0%, AMHD screens cheaper than that median.
Fair Value models
Bear $0.0002Fair Value $0.0002Bull $0.0002
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: only 1 usable fiscal years, at least 4 required
Compare HLK Biotech Holding Group Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 585 stocks
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "HLK Biotech Holding Group Inc Fair Value". https://www.fairvalue-calculator.com/stock/AMHD
Frequently asked questions
Is HLK Biotech Holding Group Inc (AMHD) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of $0.0002 versus the last price from Sep 25, 2026 of $0.0002, about +0% upside (fairly valued).
What is the fair value of AMHD?
Our model-based fair value for HLK Biotech Holding Group Inc is $0.0002 (as of Sep 27, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $0.0002.
What is the quality score of AMHD?
HLK Biotech Holding Group Inc has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for HLK Biotech Holding Group Inc (AMHD)?
Our model-based price target is the fair value of $0.0002 (as of Sep 27, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the HLK Biotech Holding Group Inc stock forecast for 2026?
Our models put fair value at $0.0002, about +0% upside versus the last price from Sep 25, 2026 of $0.0002 (fairly valued). The calculation is refreshed regularly with new filings.
What is the intrinsic value of HLK Biotech Holding Group Inc (AMHD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For HLK Biotech Holding Group Inc it is $0.0002 per share (as of Sep 27, 2026), against a price of $0.0002. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is HLK Biotech Holding Group Inc stock overvalued or undervalued in 2026?
As of Sep 27, 2026, AMHD trades below its calculated fair value: price $0.0002, fair value $0.0002, a gap of about +0% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AMHD?
No. The price is what the market pays today ($0.0002); the fair value is what the company's own numbers justify ($0.0002). For HLK Biotech Holding Group Inc the two are $0.0000 per share apart. That gap is exactly why we show both numbers side by side.
How much is HLK Biotech Holding Group Inc worth?
The market values HLK Biotech Holding Group Inc at about $1.3K (market capitalisation, as of Sep 27, 2026). Per share that is $0.0002; our models calculate a fair value of $0.0002 per share.
How solid is the balance sheet of HLK Biotech Holding Group Inc (AMHD)?
Balance-sheet figures for HLK Biotech Holding Group Inc (as of Sep 27, 2026): debt of 0.32 per unit of equity. They feed the Quality Score of 31/100, which measures business quality independently of the share price.
How far is AMHD from its 52-week high?
HLK Biotech Holding Group Inc trades at $0.0002, at its 52-week high of $0.0002 and at the low of $0.0002 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0002 is for.
Which stocks are comparable to HLK Biotech Holding Group Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is HLK Biotech Holding Group Inc stock attractive at the current price?
The data as of Sep 27, 2026: price $0.0002, calculated fair value $0.0002 (+0%), Quality Score 31/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of AMHD calculated?
We run HLK Biotech Holding Group Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0002, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. HLK Biotech Holding Group Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of HLK Biotech Holding Group Inc (AMHD)?
The latest price we hold is from Sep 25, 2026 and stands at $0.0002. Our model-based fair value is $0.0002, about +0% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with HLK Biotech Holding Group Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of HLK Biotech Holding Group Inc
How large is the market capitalisation of HLK Biotech Holding Group Inc (AMHD)?
The market capitalisation of HLK Biotech Holding Group Inc is $1.3K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the net margin of HLK Biotech Holding Group Inc (AMHD)?
The net margin of HLK Biotech Holding Group Inc is −45.3% (fiscal year 2016). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of HLK Biotech Holding Group Inc (AMHD)?
On an EBIT basis the return on assets of HLK Biotech Holding Group Inc is −335% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of HLK Biotech Holding Group Inc (AMHD)?
The operating margin of HLK Biotech Holding Group Inc is −159% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
Free · no account needed
Watch HLK Biotech Holding Group Inc in the live analysis
One click puts HLK Biotech Holding Group Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 27, 2026